Arch Oncology
Biotechnology, 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States, 11-50 Employees
Who is ARCH ONCOLOGY
Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with s...
Read More
- Headquarters: 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States
- Employees: 11-50
- Revenue: $5 Million to $10 Million
Industry: Biotechnology
SIC Code: 8731
Does something look wrong? Fix it. | View contact records from ARCH ONCOLOGY
Arch Oncology Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Arch Oncology
Answer: Arch Oncology's headquarters are located at 2000 Sierra Pt Pkwy Fl 700, Brisbane, California, 94005, United States
Answer: Arch Oncology's official website is https://archoncology.com
Answer: Arch Oncology's revenue is $5 Million to $10 Million
Answer: Arch Oncology's SIC: 8731
Answer: Arch Oncology has 11-50 employees
Answer: Arch Oncology is in Biotechnology
Answer: Arch Oncology contact info: Phone number: Website: https://archoncology.com
Answer: Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. Our lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, we are advancing a pipeline of antibody programs for the treatment of cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. AO-176 works by blocking the dont eat me signal for macrophages, the standard mechanism of anti-CD47 antibodies. However, beyond blocking this signal, AO-176 has additional mechanisms including both directly killing tumor cells and inducing DAMPs (Damage Associated Molecular Patterns) resulting in Immunogenic Cell Death. Importantly, AO-176 binds preferentially to CD47 on tumor cells, instead of normal cells, and binds even more potently in low pH conditions such as the tumor microenvironment. Our headquarters is in Brisbane, CA, a gateway of biotechnology innovation, and our scientific research laboratory is in St. Louis, MO, home of the Gateway Arch.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month